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Abstract
Dynamic contrast-enhanced magnetic resonance im-
aging (DCE-MRI) is widely used to evaluate tumor
permeability, yet measurements have not been di-
rectly validated in brain tumors. Our purpose was
to compare estimates of forward leakage K trans de-
rived from DCE-MRI to the estimates K obtained using
[14C]aminoisobutyric acid quantitative autoradiogra-
phy ([14C]AIB QAR), an established method of evaluat-
ing blood–tumor barrier permeability. Both DCE-MRI
and [14C]AIB QAR were performed in five rats 9 to
11 days following tumor implantation. K trans in the
tumor was estimated from DCE-MRI using the three-
parameter general kinetic model and a measured vas-
cular input function. Ki was estimated from QAR data
using regions of interest (ROI) closely corresponding
to those used to estimate K trans. K trans and Ki corre-
lated with each other for two independent sets of cen-
tral tumor ROI (R = 0.905, P = .035; R = 0.933, P = .021).
In an additional six rats, K trans was estimated on two
occasions to show reproducibility (intraclass coeffi-
cient = 0.9993; coefficient of variance = 6.07%). In vivo
blood–tumor permeability parameters derived from
DCE-MRI are reproducible and correlate with the gold
standard for quantifying blood tumor barrier perme-
ability, [14C]AIB QAR.
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Introduction
Tumor angiogenic vessels are larger, are more tortuous,
and have large endothelial fenestrations and caveoli that
make them more permeable than normal vessels. Such
vessels are thought to promote tumor growth by increasing
blood flow and nutrient delivery and are, therefore, a target for
cancer therapies. Dynamic contrast-enhanced magnetic reso-
nance imaging (DCE-MRI) is currently in wide use as a method
for monitoring vascular permeability within tumors, as a means
of assessing early response to antiangiogenic therapy in clini-
cal trials [1–3].
Despite its widespread use, there is controversy over the
physiological meaning of parameters derived from DCE-MRI,
as well as concerns over the reproducibility of such measure-
ments. To date, the only attempts to validate DCE-MRI have
been either reproducibility studies, simulations, or qualitative
comparisons to histology and immunohistochemical markers of
tumor angiogenesis such as CD31 and microvascular density
measurements [4]. Although measures of reproducibility and
qualitative comparisons to immunohistochemistry are helpful,
they are not physiologically based and, therefore, do not
directly assess vascular permeability. Indeed, there is concern
that DCE-MRI–derived parameters are more dependent on
tumor blood flow than on vascular permeability. Others have
raised concerns that an assumption of slow water exchange
between intracellular and extracellular compartments may be
incorrect and may lead to gross errors in permeability measure-
ments [5]. Studies using DCE-MRI to monitor tumor response
to vascular-disrupting agents have raised concerns about the
utility of DCE-MRI biomarkers [6]. Without comparison studies
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with ‘‘true’’ functional measures of permeability, the validity of
DCE-MRI as an index of vascular permeability is unclear,
and the true physiological meaning of the influx rate constant
(K trans) remains unknown.
In this study, we directly compare the DCE-MRI index of
vascular permeability (K trans) to a standard experimental
method of measuring the influx rate constant (Ki) of small
molecules leaking from vascular space into extravascular–
extracellular space by [14C]aminoisobutyric acid quantita-
tive autoradiography ([14C]AIB QAR) in the RG2 rat brain
tumor model [7,8]. K trans and Ki are both measures of the
permeability–surface area product per unit volume in the
RG2 tumor and, thus, should correlate with each other; yet
these measures are obtained through markedly divergent
techniques [2,8,9]. K trans is derived from a two-compartment
pharmacokinetic model based on the curve fitting of the
time–gadolinium concentration curve in the tumor. Ki is
derived from the unique characteristics of AIB, which leaks
unidirectionally from the blood into tissue and is then trapped
at the site of leakage. Ki can thus be determined from
[14C]AIB QAR data with very high spatial resolution using a
‘‘unidirectional model’’ and simple calculation [7]. In addition
to examining correlations to this ‘‘gold standard’’ measure,
the reproducibility of DCE-MRI K trans estimates is examined
for repeated RG2 tumor DCE-MRI estimates.
Materials and Methods
Animal Preparation
All studies were performed after obtaining the approval of
the institutional Animal Care and Use Committee. The main-
tenance and care of animals were in compliance with Na-
tional Institutes of Health guidelines. RG2 tumor cells were
grown in culture and implanted (1  105 cells in 5 ml of
phosphate-buffered saline) into the caudate–putamen of
five adult male Fischer-344 rats (weight range, 250–300 g;
Harlan Laboratories, Indianapolis, IN) using previously de-
scribed techniques [10]. Cells were grown in vivo for 9 to
11 days before injection. On the day of implantation, ani-
mals were anesthetized with isoflurane, and one venous and
two arterial polyethylene microtubing cannulations (PE-50;
Becton Dickinson, Franklin Lakes, NJ) were placed for ve-
nous gadolinium diethylenetriamine pentaacetic acid (Gd-
DTPA) infusion, venous [14C]AIB injection, arterial [14C]AIB
plasma concentration sampling, and arterial blood pres-
sure monitoring.
DCE-MRI Scanning
Animals were placed on a Philips Intera 3.0-T MR scanner
(Philips Medical Systems, Andover, MA) with a dedicated
7-cm rat solenoid radiofrequency coil (Philips Research
Laboratories, Hamburg, Germany) with maintenance iso-
flurane anesthesia from 9 to 11 days following tumor im-
plantation. Scout images were obtained to define a coronal
plane perpendicular to the dorsum of the rat brain for sub-
sequent imaging. For anatomic imaging, 32 two-dimensional
fast spin-echo T2 slices were acquired. For T1 mapping, a
low-flip-angle (FA = 3j) three-dimensional fast field echo
(FFE) sequence with parameters otherwise matching the
DCE-MRI scan sequence was performed immediately be-
fore dynamic scans.
DCE-MRI Thirty DCE-MRI three-dimensional T1 FFE se-
quence volumes were obtained over 10 minutes at a tem-
poral resolution of 20 sec/vol.
Geometric parameters were as follows: slice thickness =
1 mm; slice gap = 0.5 mm (oversampled); slices = 16 (32);
field of view (FOV) = 76.8 mm; matrix = 256 244—resulting
in an interpolated in-plane resolution of 0.33 mm.
Contrast parameters were: TR = 8.1 milliseconds; TE =
2.3 milliseconds; FA = 12j. Following five baseline scans,
0.5 ml/kg Gd-DTPA (Magnevist; Bayer HealthCare Phar-
maceuticals, Wayne, NJ) was injected through the femoral
vein using a Hamilton syringe (Hamilton Co., Reno, NV)
connected to a polyethylene microtubing (PE-50; Becton
Dickinson) at a constant rate of 0.5 ml/kg per minute over
1 minute, with a 2-minute saline flush using a microinfusion
pump (PHD 2000; Harvard Apparatus, Holliston, MA).
[14C]AIB QAR
[14C]AIB QAR was performed within 30 minutes of MR
scanning. Animals were transferred to a radiation-secure
facility, placed under maintenance anesthesia, and prepared
for constant-withdraw plasma sampling similar to that de-
scribed in Asotra et al. [11]. A saline-filled PE-90 tubing was
attached to the femoral artery line, and a saline-filled (1.0 ml)
Hamilton syringe (Hamilton Co.) in a Harvard pump (PHD 22/
2000; Harvard Apparatus) was set to constant withdrawal
(33 ml/min). A 0.5-ml bolus of 100 mCi (n = 6) or 33 mCi (n = 2)
of [14C]AIB was manually injected into the femoral vein over
15 seconds, 1 minute after starting the pump. After approxi-
mately 20 minutes, the pump was stopped, PE-90 blood
sample was collected, and time at the experimental end point
was documented (Te). Blood samples were collected at the
time of sacrifice. The animal was immediately guillotined,
and the brain was rapidly removed (f 5 minutes) and frozen
in 2-methylbutane. Guillotining was required in the experi-
mental design to rapidly freeze the brain and to prevent
significant diffusion of [14C]AIB away from the initial site of
leakage, and was approved as an exception by the institu-
tional Animal Care and Use Committee.
Arterial blood samples were immediately spun, plasma
samples were collected, and plasma concentrations for the
PE-90 tubing (CpðtÞ ) and the femoral line (Cp(Te)) were
measured. At an angle approximating the MR slice plane,
frozen brains were sectioned in a cryomicrotome into 40-mm
sections per 200-mm interval and photographed. Sections
were exposed on film (Fuji Photo Film, Inc., Greenwood, SC)
for 3 to 4.5 days for 100-mCi infusions (n = 6), or for 10.5 to
12 days for 33-mCi infusions (n = 2), with 40 mm [14C]AIB
standards (0–35 mCi; American Radiolabeled Chemicals,
Inc., St. Louis, MO). The use of standards allowed for
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changes in the specific radioactivity of [14C]AIB infusions
to speed up film development without affecting the accu-
racy of tissue [14C]AIB concentration determinations or the
calculation of Ki. Films were scanned using a BAS-5000
Bio-Imaging Analyzer (Fuji Medical Systems, Stamford, CT).
DCE-MRI Analysis
All DCE-MRI data were processed using an investiga-
tional pharmacokinetic analysis package (KinMod plug-in to
CINEtool; GE Healthcare, Waukesha, WI) based on IDL
(Research Systems, Inc., Boulder, CO). Precontrast T1 maps
were generated from data obtained at 3j and 12j flip an-
gles [12,13]. DCE-MRI signal was converted into Gd-DTPA
concentration.
A region(s) of interest (ROI) for vascular input function
(VIF) selection was drawn around the confluence of dural
sinuses, taking care to exclude regions with time-of-flight
inflow artifacts. Using the CINEtool program, a semiauto-
mated algorithm based on variance thresholding was used
to select an ROI, from which the VIF was calculated. Sig-
nals were converted to Gd-DTPA concentration, assuming
a normal blood T1 of 1320 milliseconds.
The VIF was convolved with general kinetic model (GKM)
transfer function using a first approximation of the three free
parameters to each Ct(t ) curve according to:
CtðtÞ ¼ ð1 fbvÞ=ð1 HctÞK trans½CbðtÞ  eK trans=ve t 
þ fbvCbðtÞ
where Cb(t ) is the VIF blood concentration per time data and
Hct is the hematocrit of Fischer-344 male rats (0.50). This
equation is identical to the bidirectional GKMmodel equation
of Iannotti et al. [14] with a conversion from plasma concen-
tration and fractional plasma volume to blood concentration
and fractional blood volume, respectively (Appendix A). The
three free parameters (K trans, fbv, and ve) were iteratively
adjusted to find a best-fit solution that minimized variance
between modeled and measured Ct(t ) curves using the
Levenberg-Marquardt method. Estimates of K trans, ve, and
fbv were made both on a voxelwise basis and by using ROI
in which signal was averaged within the ROI.
Three ROI were hand-drawn on T1-weighted images at
peak contrast enhancement, approximately 5 minutes after
the injection of contrast media. The mean value of the
three regions for contrast–enhancement ratio (CERc), the
ratio of enhancement signal to baseline signal, was mea-
sured. A CINEtool function automatically generated ROI with
boundaries equal to 25%, 50%, and 75% of the CERc for
each animal.
[14C]AIB QAR Analysis
Optical density measurements of autoradiographs were
converted to tissue concentration using 40-mCi standards
and a polynomial fit of the curve of optical density versus
tissue radioactivity per volume using MATLAB (MathWorks,
Natick, MA). Autoradiograph pixelwise concentration and Ki
maps were generated according to:
Ki ¼ ðCt  fpvCpðTeÞÞ=
Z
CpðtÞdt
Z
CpðtÞdt ¼ CpðtÞT
where Ct is the pixel tissue concentration; the fractional
plasma volume (fpv) is assumed to be 2.2% based on prior
studies [15]; T is the time of actual sample withdrawal during
total experimental time (Te); Cp(Te) is the plasma concentra-
tion at Te; and CpðtÞ is the concentration of radioactive
plasma collected during T. Using a constant rate of sample
withdrawal, the integral
R
CpðtÞdt solves to CpðtÞT .
A radiologist blinded to the study results analyzed ana-
tomic landmarks in gross brain photographs, T2 images, and
postcontrast T1 images to select three [
14C]AIB QAR section
autoradiographs to match MR sections. [14C]AIB QAR ROI
were semiautomatically generated using the image process-
ing software MIPAV (http://mipav.cit.nih.gov; National Insti-
tutes of Health, Bethesda, MD). The [14C]AIB QAR tumor
ROI aimed to match the 25% DCE-MRI ROI were first
generated. For each [14C]AIB concentration map, ROI were
drawn in the brain region contralateral to the tumor to plot the
mean and distribution of normal tissue ‘‘background’’ con-
centration values, and the value at 3 SD above the mean
background value (BG3SD) was recorded. A mask over each
tumor section was then created with edges at each individu-
ally determined BG3SD threshold. This mask was then used
to generate the QAR ROI at the tumor edge, approximating
the volume of the 25% DCE-MRI ROI. To generate the QAR
ROI matching the 50% and 75% threshold DCE-MRI ROI,
concentration threshold values were increased until the
volume of the generated QAR mask approximated the
volume of the corresponding 50% or 75% DCE-MRI ROI.
The final [14C]AIB QAR ROI were then copied and pasted
to [14C]AIB QAR pixelwise influx rate constant (Ki) maps.
The mean Ki value, standard deviation, and volume were
recorded for each QAR Ki map. A final [
14C]AIB QAR Ki
value corresponding to each DCE-MRI slice was deter-
mined as the mean measure of the three selected [14C]AIB
QAR sections.
Statistics
Regression statistics were generated for K trans versus Ki
for each ROI pair of central tumor slices (SPSS, Chicago, IL).
Reproducibility Studies
In a separate set of experiments on a separate population
of six Fischer-344 rats, test–retest repeat DCE-MRI studies
were performed between 14 and 24 hours after the first
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injection of Gd-DTPA. DCE-MRI ROI for each experiment
were obtained using hand-drawn ROI to be consistent with
commonly used techniques. A user was instructed to select
a central slice and to draw ROI (n = 5) within but closely
approximating tumor edges to exclude a boundary of ap-
proximately 0.5 mm from the tumor edge for all scan MR
central slice data. VIFs were then chosen, and parameter
estimates were generated as described previously. To re-
duce variance due to hand-drawn ROI, the value for test–
retest scans was calculated as the mean of five K trans
estimates for five tumor ROI.
Reproducibility Statistics
Reproducibility statistics included the intraclass correla-
tion coefficient (ICC), coefficient of variation (CoV), and
within-subject standard deviation (wSD). (Microsoft Excel,
Redmond, WA) [16–20].
Results
Tumors were successfully implanted and grown in 11
Fischer-344 rats. [14C]AIB autoradiography and DCE-MRI
data were completed and analyzed on five of these animals,
whereas repeat DCE-MRI test–retest studies were com-
pleted on the remaining six animals.
DCE-MRI Ktrans versus [14C]AIB QAR Ki
Ki maps generated from [
14C]AIB QAR autoradiographs
and K trans maps generated from DCE-MRI voxelwise data for
the central tumor slice of each animal are shown (Figure 1).
Similarities in the topographies of K trans and Ki maps can be
appreciated, with higher influx rate constants in the central
tumor and lower influx rate constants peripherally in both
K trans and Ki maps. Note that distortions from tissue ‘‘chatter’’
caused by displacement during cryomicrotome tissue slicing
in [14C]AIB QAR Ki maps are not present in in vivo DCE-MRI
K trans parameter maps.
Tumor ROI, autoradiography Ki measures, and DCE-MRI
measures of K trans, kep, ve, and fbv are listed for each tumor
ROI for each animal (Table 1). The mean percentile differ-
ences in transfer constants between autoradiography and
DCE-MRI (mean ± SD) were 2.88 ± 9.51%, 1.33 ±
2.28%, and 5.98 ± 26.2% for the 75%, 50%, and 25%
thresholds, respectively.
For the central tumor 75% threshold, K trans (mean ± SD)
measured with DCE-MRI was 0.0630 ± 0.0253, and the cor-
responding [14C]AIB autoradiography Ki measure (mean ±
SD) was 0.0209 ± 0.0104. The fractional extravascular–
extracellular space ve (mean ± SD) was 17.6 ± 3.2%. The
fractional blood volume (mean ± SD) was 2.80 ± 1.3%.
Mean DCE-MRI parameter estimates were comparable to
published measures for central tumor regions obtained using
radiolabeled serum albumin for ve and fbv (7.5% and 3.2%,
respectively) [15,21]. DCE-MRI experimental measures of
ve were 2.3-fold higher than published measures for RG2
tumors. For fractional blood volume (fbv), the percentile dif-
ference between experimental measures and published
measures in RG2 tumors was only 12.5%.
DCE-MRI K trans and [14C]AIB QAR Ki maps display the
variation and range of influx rate constants measured across
the tumors (Figure 1). K trans and Ki heterogeneity varied
together on a pixel-by-pixel basis. DCE-MRI K trans versus
[14C]AIB QAR Ki were plotted for the 75%, 50%, and 25%
threshold ROI for central tumor slices (Figure 2). For the
central 75% threshold, K trans and Ki influx rate constants
were positively correlated (slope ± SEM = 2.190 ± 0.594; R =
0.905; R2 = 0.819; adjusted R2 = 0.759; F = 13.6; P = .034).
For the central 50% threshold, the slope decreased, but R
increased (slope ± SEM = 1.838 ± 0.411; R = 0.933; R2 =
0.870; adjusted R2 = 0.826; F = 20.0; P = .021).
Tumor ROI incorporating increasing proportions of the
tumor edge were analyzed to study the impact of tumor
periphery on DCE-MRI parameter estimates. Examples of
ROI and corresponding histograms of K trans voxelwise data
and Ki pixelwise data are shown for animal 1 (Figure 3).
Despite distortions related to tissue sectioning, the strategy
employed for ROI selection was qualitatively accurate in
selecting the same tumor tissue in both [14C]AIB QAR auto-
radiographs and DCE-MRI maps. Lowering the ROI thresh-
old resulted in larger ROI with more tumor periphery.
Histograms of Ki from QAR data were unimodal for all three
ROI thresholds. Histograms of K trans from DCE-MRI data
were unimodal for the central tumor 75% threshold, but
were bimodal for the 25% and 50% thresholds with more
tumor periphery. This ‘‘noise,’’ which is seen as a sec-
ondary high-amplitude peak of low K trans on histograms of
DCE-MRI voxelwise data, can be qualitatively appreciated
as a rim of low K trans values at tumor edges in K trans maps
(Figure 1).
A comparison of influx rate constants derived from DCE-
MRI and QAR using different ROI demonstrated a systematic
decrease in K trans relative to Ki as more of the tumor periph-
ery was included in tumor ROI. The slope of regression line
(slope ± SEM) for K trans versus Ki decreased systematically
from 2.190 ± 0.594, to 1.838 ± 0.411, to 1.443 ± 0.483 for
the 75%, 50%, and 25% threshold ROI, respectively. For the
25% threshold ROI that included the highest proportion of
tumor periphery, the correlation between K trans and Ki mea-
sures was not statistically significant (R = 0.865; R2 = 0.749;
adjusted R2 = 0.665; F = 8.94; P = .058).
DCE-MRI K trans Reproducibility
There was positive reproducibility of K trans estimates for
repeat DCE-MRI experiments on a separate population of
animals with implanted RG2 tumors (n = 6) (Figure 4). The
mean (± SD) K trans for the first test was 0.0759 ± 0.130, and
the mean (± SD) K trans for the second test was 0.0798 ±
0.139. Test–retest K trans estimates had an ICC of 0.9993 and
a regression coefficient (R) of 0.9997 (P < .001). The CoV was
10.2%, and the wSD was 0.00323. The 95% confidence
interval for measurement error was ± 20.1% or ± 0.00633.
Given that there was systematic offset in the data, it was
alternately analyzed to more closely approximate ‘‘true’’ mea-
surement error. The second K trans estimate was consistently
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higher than the first estimate (mean ± SEM = 0.00385 ±
0.0011). Closely timed studies were required in these fast-
growing tumors, and this systematic offset was likely due to
the effects of residual contrast in tumors on the second day
of Gd-DTPA injection, but could have been caused also by
tumor changes. According to accepted statistical methods,
systematic changes between scans can be accounted for
by subtracting the mean difference between subjects’ scans
from the second scan values [18]. After adjusting for system-
atic offset, the CoV was 6.07%, and the wSD was 0.00174.
The 95% confidence interval for a given measurement was ±
11.9% or ± 0.00341. The repeatability (r ) was 16.8% or
0.00482. Therefore, a difference of 16.8% or 0.00482 in two
independent tumor measurements using this method in a sin-
gle tumor represents a true tumor change in K trans.
Reproducibility results were similar for the analysis of
data from five animals and excluding the high K trans value.
The data, excluding this high value, (Figure 4, inset) are on
virtually the same line as the data for all six animals. The ICC
is lower due to the decreased range in data, with a value
of 0.9152. After adjusting for systematic offset, however,
the CoV and wSD for five animals were very similar to the
results for the six animals. The CoV was 6.63%, and the
wSD was 0.00135. The 95% confidence interval for a given
measurement was ± 13.0% or ± 0.00265. The repeatability
(r ) was 18.4% or 0.00374.
Discussion
DCE-MRI is in wide clinical use and has proven useful in
detecting early changes in vascularity after angiogenic in-
hibitor treatment. Wedam et al. [22] used methods similar to
this DCE-MRI method, with Gd-DTPA and the same IDL
software package, to demonstrate changes in K trans in breast
cancer patients during treatment with bevacizumab, a vas-
cular endothelial growth factor inhibitor. However, in spite of its
wide use, the interpretation of K trans values is still uncertain.
Figure 1. (A) [14C]AIB QAR Ki maps. (B) DCE-MRI K
trans parameter maps for
central tumor slices for each animal. DCE-MRI K trans parameter maps are
displayed within the 25% threshold ROI.
Table 1. [14C]AIB QAR Influx Rate Constant (Ki) Measures and DCE-MRI Parameter Estimates of the Influx Rate Constant (K
trans), Efflux Rate Constant (kep),
Fractional Leakage Space Volume (ve), and Fractional Blood Volume (fbv) for 75%, 50%, and 25% Threshold ROI and ROI Areas for Central Tumor Slices.
Animal Tumor Days Threshold (%) Ki (min
1) Area (mm2) Ktrans (min1) Area (mm2) Differential Ratio of Tumor Area kep (min
1) ve fbv
1 9 25 0.0272 9.1 0.0420 9.9 0.088 0.443 0.096 0.03
50 0.0306 7.3 0.0660 7.2 0.014 0.546 0.123 0.02
75 0.0346 5.4 0.0900 5.4 0.000 0.641 0.141 0.01
2 11 25 0.0208 24.3 0.0480 20.3 0.165 0.321 0.150 0.04
50 0.0254 15.6 0.0690 15.6 0.000 0.387 0.174 0.03
75 0.0273 11.3 0.0900 11.2 0.009 0.459 0.198 0.02
3 10 25 0.0126 11.6 0.0180 7.2 0.379 0.174 0.096 0.03
50 0.0172 3.8 0.0360 3.6 0.053 0.268 0.132 0.04
75 0.0185 2.6 0.0420 2.1 0.192 0.283 0.144 0.04
4 10 25 0.0121 13.0 0.0240 11.1 0.146 0.192 0.126 0.04
50 0.0160 6.2 0.0420 6.2 0.000 0.249 0.168 0.03
75 0.0171 3.9 0.0540 3.9 0.000 0.254 0.210 0.03
5 11 25 0.0055 9.9 0.0180 12.9 0.303 0.146 0.126 0.04
50 0.0060 7.1 0.0270 7.1 0.000 0.168 0.162 0.05
75 0.0072 3.5 0.0390 3.7 0.057 0.209 0.186 0.04
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The results of the current study demonstrate a significant
correlation between DCE-MRI–derived K trans and [14C]AIB
QAR–derived Ki in the RG2 tumor model. [
14C]AIB QAR is a
long-established quantitative method of measuring vascular
leakage for small molecules, and this result is therefore useful
in confirming that K trans is highly related to vascular perme-
ability, at least in some animal tumor models. Thus, although
offset by a factor of roughly 2 in absolute value, DCE-MRI
estimates are predictors of ‘‘gold standard’’ measurements of
vascular permeability. Differences in the biophysical proper-
ties of AIB and DTPA likely account for these small differ-
ences. Permeability is a function of the characteristics of the
molecule transiting the membrane, such as surface charge,
molecular weight, ionization, lipophilicity, and shape. Gd-
DTPA (547 Da) is a charged and extremely hydrophilic
molecule, whereas AIB (102 Da) is a synthetic amino acid
that is neutral and hydrophilic [7,23]. Thus, within practical
experimental limits, these two agents produced remarkably
similar results.
Although there was a strong correlation betweenK trans and
Ki in central tumor regions, the correlation was weaker when
the periphery of the tumor was included. There was a mea-
sured decrease in [14C]AIB QAR Ki values at RG2 tumor
edges consistent with prior results for the RG2 model, and
partial volume effects of normal and tumor tissues near the
edge are expected to lower DCE-MRI K trans [24]. The low
K trans values seen at the tumor edge were thus likely due to
partial volume effects. RG2 tumors are also known to be
edematous [25], and it is possible that this effect contributed
to the lowering of K trans values at tumor edges. The effect
of variance in K trans relative to Ki as more of the periphery
is included in the measurement is reflected in the change
in slope in the line of regression (Figure 2). The two-fold
decrease in K trans values between the 75% threshold and
the 25% threshold demonstrates the impact of tumor edge
‘‘noise’’ and the need for strategies of ROI selection that avoid
these edge effects. The impact of partial volume effects on
tumor edges and necrotic regions, however, is expected to be
lower in human studies, which generally include tumors larger
than those evaluated in this model.
Measures of K trans obtained using DCE-MRI proved
highly reproducible in this study. A high correlation was
observed with two independent repeated measurements.
This has implications for the magnitude of the therapeutic
effect required to be measurable by DCE-MRI. Galbraith et
al. demonstrated that ‘‘failed’’ pixel data had to be removed to
reduce interscan variability and that a relatively large vari-
ance was required to show statistical changes in human
tumors even after data exclusion. Changes of 45% to 83%
were needed to overcome the CoV of 24% to 29% in
conventional studies [19]. Liu et al. [26] thus used a decrease
of > 50% in K trans to detect a real change in advanced tumors
treated with the angiogenic inhibitor AG-013736. Recent
studies of reproducibility in human abdominal tumors, glio-
mas, and prostate malignancies using an assumed VIF
showed similar results requiring changes of > 31% to
> 44% (CoV = 11–16%) in one study and a measurement
error of > 16% (CoV = 8.2%) in another [20,27]. The ICC,
CoV, and 95% confidence interval for measurement error in
this study compared favorably to prior results. The improved
reproducibility in our model can be traced to improved VIFs,
reliable pulse sequences, and a two-compartment model
with a sufficient number of parameters to fit most of the
pixels within the tumor. Reproducibility results from clinical
and preclinical DCE-MRI are, however, highly variable. Such
studies often reported pixel ‘‘failures’’ (i.e., inability to fit the
data to the model) and reported pixel exclusion ranging
Figure 2. DCE-MRI K trans versus [14C]AIB QAR Ki for central tumor slices for
the (A) 75%, (B) 50%, and (C) 25% threshold ROI.
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between 13% and 74% [19,28]. However, the DCE-MRI
method used in this study required no filtering or removal
of pixel data within the ROI. This is likely because the
modeling allowed better fitting of measured data and be-
cause tightly controlled experimental conditions led to robust
data sets. Although one study reported a CoV of 7.7% after
significant pixel data exclusion (mean = 39%) [28], we were
able to achieve a 95% confidence interval of an individual
K trans measure of ± 0.00341 (± 11.9%) (ICC = 0.9993; CoV =
6.07%) with no pixel data exclusion. The precision of DCE-
MRI was predictable from strong correlation results with
[14C]AIB QAR Ki measures because the ability to detect
a correlation is related to the precision of independent mea-
sures. Although a correlation is possible with ‘‘noisy’’ data
using a large number of experiments, statistical correla-
tion was demonstrated in this study using only a small
number of animals suggesting a relatively high precision of
the DCE-MRI method.
The successful use of a VIF certainly contributed to the
robustness of this technique. Direct measurement of arterial
blood was not possible in this model given the small size of
vessels in small animals, and the VIF was instead measured
from venous sinus blood. A similar technique using measure-
ments of VIF from the sagittal sinus has been used in human
DCE-MRI studies [28]. Although several groups have used
slow injections in pharmacokinetic modeling [29], it is argued
that a bolus injection is needed for accurate mathematical
modeling of Gd-DTPA kinetics [5,28,30]. The results of this
study suggest that a slow bolus allows for accurate and
precise parameter estimates. Furthermore, a fast bolus re-
quires rapid data acquisition with reduced signal-to-noise
ratios to accurately measure the VIF. Finally, a longer acqui-
sition interval allows for a larger FOV and higher-resolution
images, which are advantageous for clinical studies. Recent
simulations and experimental data using this DCE-MRI
method suggest that there is no significant difference in K trans
estimates using a slow injection versus a bolus injection in
patient studies (unpublished observations). If correct, a slow
injection may be more satisfactory for DCE-MRI in the clinical
setting than was originally thought because a high-resolution
large FOV is often needed.
In this experiment, it was not possible to correlate other
DCE-MRI parameters, such as kep, with [
14C]AIB QAR be-
cause the latter only measures the forward leakage rate. Two
Figure 3. Sample images of tumor ROI and corresponding histograms for animal 1. (A) Images of DCE-MRI ROI (white) for the 25%, 50%, and 75% thresholds.
(B) Images of corresponding [14C]AIB QAR ROI (white). (C) Histograms of DCE-MRI K trans voxelwise data for the corresponding DCE-MRI ROI threshold with
polynomial fit trendlines. (D) Histograms of [14C]AIB QAR Ki pixelwise data for the corresponding [
14C]AIB QAR ROI threshold.
Figure 4. Test – retest K trans estimates from repeat DCE-MRI experiments for
all subjects and excluding the highest K trans data point (inset).
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other free parameters were estimated from the best-fit solu-
tion of the GKM: fbv and ve. Although parameter estimates of
fractional blood (fbv) and leakage space volumes (ve) were
comparable to published measures using other techniques
for RG2 tumors, leakage space estimates showed greater
variation from prior published values. Zhou et al. [31] have
shown that measures of ve obtained using a method similar
to that used in this study can vary based on the dosing of
Gd-DTPA when corrections are not made to account for the
effects of transcytolemmal water exchange on tissue relax-
ivity. Based on these results, the values of ve obtained in this
study would be expected to have varied for different doses of
Gd-DTPA. It may, therefore, be necessary to make such cor-
rections to obtain accurate DCE-MRI ve measures.
This study has a number of limitations. We cannot dis-
count the possibility that the good correlation between K trans
and Ki may be related to the nature of the RG2 model. In
vessels where flow is high relative to permeability, such as
in the RG2 model, the rate of influx of AIB and Gd-DTPA
from the vessel to the tumor is a function of vascular perme-
ability [2,8,9]. In tumor regions with lower blood flow, K trans
may be more dependent on flow than on permeability and,
therefore, may not accurately depict vascular permeability. A
broader range of tumor models is needed to confirm the
validity of DCE-MRI parameters for predicting vascular per-
meability across a range of tumor blood flow rates. By ex-
amining K trans estimates in a permeability-limited high-flow
tumor model, this study allowed K trans estimates to be sim-
plified to indices of permeability—the parameter that is po-
tentially most valuable for monitoring treatment effects on
angiogenic tumor vasculature.
Additional limitations of this study include technical chal-
lenges in comparing in vivo MRI and invasive QAR meth-
ods. There was considerable distortion of tissues using the
[14C]AIB QAR technique due to shearing, warping, and
tearing, and matching DCE-MRI and [14C]AIB autoradio-
graph tissue regions was technically difficult. The strategy
employed, including the use of large computer-generated
ROI and central tumor slices, reduced misregistration error.
In the future, macromolecular contrast agents may be
better measures of permeability by separating flow effects
from K trans indices of permeability [32–34]. This effect would
be most prominent in areas with a high permeability-to-flow
ratio. Macromolecular agents have been used in preclinical
DCE-MRI tumor studies, but these techniques are not yet
ready for clinical studies because these macromolecular
agents have not yet been approved by regulatory agen-
cies for human use and because techniques used in these
studies, such as ex vivo VIF measurements, are not easily
applied to clinical studies [35]. QAR validation of macromo-
lecular contrast agents will require a radioisotopically labeled
macromolecule of similar hydrodynamic diameter, hydrophi-
licity, and surface charge as the MR-based macromolecular
agent. The advantages of using low-molecular-weight Gd-
DTPA versus higher-molecular-weight agents include the
increased penetration of smaller compounds in areas of
decreased permeability and the general availability and
established safety of Gd-DTPA.
In summary, this study demonstrates a statistical corre-
lation between direct measures of the influx (or forward leak-
age) rate constant obtained using DCE-MRI (K trans) and
direct measures of the influx (or forward leakage) rate con-
stant obtained using the ‘‘gold standard’’ method [14C]AIB
QAR (Ki).
Appendix
List of Terms
Ce(t ) Extravascular–extracellular space (or leakage
space) tracer concentration
K trans DCE-MRI influx rate constant (or volume transfer
constant)
Cp Plasma tracer concentration
ve Fractional extravascular–extracellular space (or
leakage space) volume
Ct Tissue tracer concentration
 Convolution
Cb(t ) Blood tracer concentration per time; VIF
fbv Fractional blood volume
fpv Fractional plasma volume
Vrbc Red blood cell volume
Vroi Volume of VIF
Derivation of GKM Bidirectional Pharmacokinetic Model
Convolution equation for bidirectional exchange between
plasma and leakage space (extravascular–extracellular space)
CeðtÞ ve ¼ K trans CpðtÞ  eK trans=ve t ð1Þ
C tðtÞ ¼ CeðtÞ ve ð2Þ
C tðtÞ ¼ K trans CpðtÞ  eK trans=ve t ð3Þ:
Plasma concentration as a function of blood concentration
CpðtÞ ¼ ðCb VroiÞ=ðVroi  VrbcÞ ð4Þ
Vrbc ¼ HctVroi ð5Þ
Cp ¼ Cb=ð1 HctÞ ð6Þ:
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Substitution of plasma concentration for blood concentration
C tðtÞ ¼ K transCbðtÞ=ð1 HctÞ  eK trans=ve t ð7Þ:
Balanced equation for the total number of particles in
tissue ROI or voxel
C totalðtÞVtotal ¼ C tðtÞ ð1 fbvÞVtotal þ CbðtÞ fbv Vtotal ð8Þ
C totalðtÞ ¼ C tðtÞ ð1 fbvÞ þ CbðtÞ fbv ð9Þ:
Therefore:
C total ¼ K trans CbðtÞð1 fbvÞ=ð1 HctÞ  eK trans=ve t
þ CbðtÞ fbv:
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